HUNTSVILLE, AL (WAFF) - A Huntsville-based diagnostic company announced Wednesday it has begun clinical studies for their a product that, if met with regulatory approval, could help doctors treat bloodstream infections more quickly.
iCubate will seek clearance from the Food & Drug Administration as an in-vitro diagnostic test to be used for the identification and detection of "gram-positive" bacteria, which are the most common cause of bacterial bloodstream infections.
Gram-positive bacteria, such as Staphylococcus, are the most common bacterial contaminants of blood. FDA approval of the iCubate system has the potential to help physicians better diagnose and treat bloodstream infections.
"In order to provide the best treatment to patients, physicians need an accurate diagnosis," said iCubate founder and chairman Jian Han, M.D.
Other processes within the iCubate system would help doctors detect antibiotic resistance to further aid in diagnoses.
iCubate is located within the HudsonAlpha complex in Huntsville.